SV2A and Alzheimer disease: The potential of these novel in vivo synaptic markers has recently been illustrated, with a reduction in hippocampal density visible in AD compared to cognitively normal controls using PET imaging of synaptic vesicle glycoprotein 2A (SV2A) [42].